Poorer survival in obese colorectal cancer patients possibly linked to lower chemotherapy doses eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Share
Experts at the University of Nottingham will investigate possible treatments for cholangiocarcinoma (bile duct cancer) as part of a new collaboration with the AMMF, the UK’s only cholangiocarcinoma charity.
Cholangiocarcinoma, is a particularly deadly disease with limited treatment options, and so new treatments are urgently needed. As part of a new collaboration, AMMF will support PhD student Grace Martin from the University’s School of Medicine, along with her supervisor Dr Sheela Jayaraman, to investigate new treatments for the disease.
The project is based on the finding that specific proteins known as transcription factors are higher in cholangiocarcinoma and are responsible for driving tumour growth and tumour invasion. As part of the new research, Grace will explore new ways to decrease the amount of these proteins in the tumour.
05 May 2021 aaj ka rashifal today horoscope in hindi daily zodiac | 05 May 2021 राशिफल: आज का राशिफल (Today s Horoscope) haribhoomi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from haribhoomi.com Daily Mail and Mail on Sunday newspapers.
1
1Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, United States
2Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, United States
3Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, United States
4Department of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL, United States
Tumor-stromal interactions within the tumor microenvironment (TME) influence lung cancer progression and response to therapeutic interventions, yet traditional
in vitro studies fail to replicate the complexity of these interactions. Herein, we developed three-dimensional (3D) lung tumor models that mimic the human TME and demonstrate tumor-stromal crosstalk mediated by extracellular vesicles (EVs). EVs released by tumor cells, independent of p53 status, and fibroblasts within the TME mediate
Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline
News Provided By
Share This Article
/EIN News/ PALO ALTO, Calif., April 01, 2021 (GLOBE NEWSWIRE) Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced the formation of its Scientific Advisory Board (SAB) composed of world leading academics and industry leaders in cancer research and therapeutics. John C. Byrd, M.D., will serve as Chairman of the SAB.
“The Vincerx team is thrilled to welcome globally recognized key opinion leaders in hematologic malignancies and oncology drug development to our newly formed SAB,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. “Their collective expertise aligns with the advancement of our diversified oncology pipeline and will be critical as we expand our research and development efforts and p